COST-EFFECTIVENESS OF ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN CHILE

被引：0
|
作者：
Elgart, J. F. [1 ]
Gonzalez, L. [1 ]
Aiello, E. C. [2 ]
机构：
[1] UNLP CONICET La Plata, Ctr Colaborador OPS OMS, CENEXA Ctr Endocrinol Expt & Aplicada, La Plata, Buenos Aires, Argentina
[2] Bristol Myers Squibb, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A223 / A223
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate
    Vera-Llonch, M.
    Massarotti, E.
    Wolfe, F.
    Shadick, N.
    Westhovens, R.
    Sofrygin, O.
    Maclean, R.
    Yuan, Y.
    Oster, G.
    RHEUMATOLOGY, 2008, 47 (04) : 535 - 541
  • [2] THE COST-EFFECTIVENESS OF ABATACEPT IN COMBINATION WITH METHOTREXATE FOR THE TREATMENT OF PATIENT WITH ACTIVE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN THE UNITED KINGDOM
    Lebmeier, M.
    Pericleous, L.
    Drost, P.
    Dequen, P.
    Ouwens, M.
    Bergman, G.
    Baig, H.
    VALUE IN HEALTH, 2010, 13 (07) : A309 - A309
  • [3] Cost-effectiveness of treatment strategies for rheumatoid arthritis patients with inadequate response to methotrexate
    Patel, VD
    Hay, J
    VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
  • [4] Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate in Brazil
    Alves, M. R.
    Carvalho, F., Jr.
    Litalien, G.
    VALUE IN HEALTH, 2008, 11 (03) : A260 - A260
  • [5] Cost effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate
    Vera-Llonch, M.
    Massarotti, E.
    Shadick, N.
    Wolfe, F.
    Westhovens, R.
    Maclean, R.
    Li, T.
    Oster, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 277 - 277
  • [6] Time to treatment response with abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate
    Kremer, J. M.
    Westhovens, R.
    Le Bars, M.
    Lafosse, C.
    Gaillez, C.
    Koncz, T.
    Schmidely, N.
    Dougados, M.
    Schiff, M.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S308 - S308
  • [7] CANADIAN COST-EFFECTIVENESS ANALYSIS OF ABATACEPT (ORENCIA™) FOR THE MANAGEMENT OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
    Zou, D.
    Desjardins, O.
    Tsao, N.
    Goeree, R.
    VALUE IN HEALTH, 2010, 13 (03) : A128 - A128
  • [8] ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    VALUE IN HEALTH, 2013, 16 (03) : A223 - A224
  • [9] COST-EFFECTIVENESS OF EARLY TREATMENT OF ACPA POSITIVE RHEUMATOID ARTHRITIS PATIENTS WITH ABATACEPT
    Neubauer, A. S.
    Minartz, C.
    Herrmann, K. H.
    Postema, R.
    Baerwald, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 442 - 443
  • [10] A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY
    Brodszky, V
    Borgstrom, F.
    Arnetorp, S.
    Pentek, M.
    Gulacsi, L.
    VALUE IN HEALTH, 2008, 11 (06) : A549 - A550
12345